Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements

References

• Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017 Jun 20;135(25):e1159–e1195.
   Google Scholar
• Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001 Jan;119(1 Suppl):220S–227S.
   Google Scholar
• Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017 Sep;38(36):2739–2791.
   Google Scholar
• Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 Jan;119(1 Suppl):8S–21S.
   Google Scholar
• Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012 Jun;163(6):931–937 e1.
   Google Scholar
• Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017 Mar 28;135(13):1273–1275.
   Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206–1214.
   Google Scholar
• El-Battrawy I, Baumann S, Huseynov A, et al. New oral anticoagulation after heart valve replacement. Cardiovasc Hematol Disord Drug Targets. 2015;15(2):106–109.
   Google Scholar
• Gasparovic H, Petricevic M, Biocina B. Dabigatran in patients with mechanical heart valves. N Engl J Med. 2014 Jan 23;370(4):383.
   Google Scholar
• Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 Oct;90(4):625–629.
   Google Scholar
• International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753–764.
   Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017 Sep;102(3):397–404.
   Google Scholar
• Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31;382(9894):790–796.
   Google Scholar
• Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006 Mar;79(3):197–205.
   Google Scholar
• Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009 Mar;5(3):e1000433.
   Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 Dec 12;369(24):2283–2293.
   Google Scholar
• Arwood MJ, Deng J, Drozda K, et al. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: a proposal for a new pharmacogenetic dosing approach. Clin Pharmacol Ther. 2017 May;101(5):675–683.
   Google Scholar
• Xu Z, Zhang SY, Huang M, et al. Genotype-guided warfarin dosing in patients with mechanical valves: a randomized controlled trial. Ann Thorac Surg. 2018 Dec;106(6):1774–1781.
   Google Scholar
• Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing–recalibrating expectations. N Engl J Med. 2013 Dec 12;369(24):2273–2275.
   Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406–1415.
   Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–2104.
   Google Scholar
• Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280–2287.
   Google Scholar
• Vandell AG, Walker J, Brown KS, et al. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800–1805.
   Google Scholar
• Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015 Jan;25(1):33–41.
   Google Scholar
• Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993 Mar 1;69(3):236–239.
   Google Scholar
• Dong L, Shi YK, Xu JP, et al. The multicenter study on the registration and follow-up of low anticoagulation therapy for the heart valve operation in China. Chin Med J (Engl). 2016 May 24;96(19):1489–1494.
   Google Scholar
• Committee of guideline for the management of patients with thrombotic diseases in China. Guideline for the management of patients with thrombotic diseases in China. Chin Med J (Engl). 2018 Sep 25;98:(36):2861–2888.
   Google Scholar
• Katada Y, Nakagawa S, Nishimura A, et al. Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery. Eur J Clin Pharmacol. 2019 Apr;75(4):561–568.
   Google Scholar
• Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010 Jan;8(1):202–204.
   Google Scholar
• Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019 Jan;133(5):425–435.
   Google Scholar
• Martin-Perez M, Gaist D, de Abajo FJ, et al. Predictors of over-anticoagulation in warfarin users in the UK general population: a nested case-control study in a primary health care database. Thromb Haemost. 2019 Jan;119(1):66–76.
   Google Scholar
• Aimo A, Giugliano RP, De Caterina R. Non-Vitamin K antagonist oral anticoagulants for mechanical heart valves. Circulation. 2018 Sep 25;138(13):1356–1365.
   Google Scholar
• Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 Feb 27;353(9154):717–719.
   Google Scholar
• Dean L. Warfarin therapy and VKORC1 and CYP genotype. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012:95–408.
   Google Scholar
• An SH, Lee KE, Chang BC, et al. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. J Clin Pharm Ther. 2014 Jun;39(3):314–318.
   Google Scholar
• Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010 May 6;115(18):3827–3834.
   Google Scholar
• Liu J, Guan H, Zhou L, et al. Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement. Am J Transl Res. 2019;11(4):2507–2515.
   Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11;349(11):1019–1026.
   Google Scholar
• Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994 Jun 1;120(11):897–902.
   Google Scholar
• Ohara M, Suzuki Y, Shinohara S, et al. Differences in warfarin pharmacodynamics and predictors of response among three racial populations. Clin Pharmacokinet. 2019 Feb 28;58:1077–1089.
   Google Scholar
• Xue L, Zhang Y, Xie C, et al. Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data. Eur J Clin Pharmacol. 2019 Jun;75(6):785–794.
   Google Scholar
• Roth JA, Boudreau D, Fujii MM, et al. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther. 2014 Jun;95(6):636–643.
   Google Scholar
• Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. Jama. 2017 Sep 26;318(12):1115–1124.
   Google Scholar
• Shendre A, Parmar GM, Dillon C, et al. Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. Pharmacotherapy. 2018 Jun;38(6):588–596.
   Google Scholar
• De T, Alarcon C, Hernandez W, et al. Association of genetic variants with warfarin-associated bleeding among patients of african descent. Jama. 2018 Oct 23;320(16):1670–1677.
   Google Scholar
• Wen MS, Chang KC, Lee TH, et al. Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial. Pharmacogenomics. 2017 Feb;18(3):245–253.
   Google Scholar
• Syn NL, Wong AL, Lee SC, et al. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. BMC Med. 2018 Jul 10;16(1):104.
   Google Scholar
• Mak M, Lam C, Pineda SJ, et al. Pharmacogenetics of warfarin in a diverse patient population. J Cardiovasc Pharmacol Ther. 2019;7:1074248419843530.
   Google Scholar
• Limdi NA, Brown TM, Shendre A, et al. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Pharmacogenet Genomics. 2017 Oct;27(10):347–355.
   Google Scholar
• Grzymala-Lubanski B, Svensson PJ, Renlund H, et al. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart. 2017 Feb;103(3):198–203.
   Google Scholar